SCHEMBL30367991

SCHEMBL30367991

[2H]C([2H])([2H])NC(=O)c1cncc(F)c1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.55
PTGS2 P35354 2/20 0.42
PTGS1 P23219 1/20 0.42
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
ABL1 P00519 1/20 0.39
RAF1 P04049 2/20 0.38
KDM4E B2RXH2 2/20 0.38
EGFR P00533 1/20 0.38
IDO1 P14902 1/20 0.37
CLK2 P49760 1/20 0.36
DYRK1A Q13627 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
ATM Q13315 1/20 0.35
ALDH1A1 P00352 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30147701 0.87 HCAR2 (0.60) HCAR2PTGS2PTGS1HDAC1HDAC6
SCHEMBL22644533 0.87 HCAR2 (0.60) HCAR2PTGS2PTGS1HDAC1HDAC6
SCHEMBL23243061 0.79 KDM4E (0.62) HCAR2KDM4EEGFRALDH1A1
SCHEMBL23167326 0.78 HCAR2 (0.62) HCAR2PTGS2PTGS1HDAC1HDAC6
SCHEMBL5479141 0.77 KDM4E (0.62) HCAR2PTGS2PTGS1HDAC1HDAC6
SCHEMBL29883112 0.76 HCAR2 (0.46) HCAR2HDAC1HDAC6ABL1RAF1
SCHEMBL289817 0.74 HCAR2 (0.49) HCAR2PTGS2PTGS1HDAC1HDAC6
SCHEMBL2722765 0.74 HCAR2 (0.67) HCAR2PTGS2PTGS1KDM4EATM
SCHEMBL5909485 0.73 RAF1 (0.53) HCAR2PTGS2PTGS1HDAC6RAF1
SCHEMBL1419312 0.73 ATM (0.65) HCAR2ABL1KDM4EATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117242072-A TYK2 inhibitor and application thereof 苏多生物科学有限公司 2023-12-15 CN disclosed
US-20230174553-A1 TYK2 INHIBITORS AND USES THEREOF SUDO BIOSCIENCES LIMITED (GB) 2023-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174553-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 HCAR2 2269/4885PTGS2 3218/4885PTGS1 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.